person · Reporting owner

Stuart Iain

Disclosed activity across 2 companies

Tapewire entity: 28717
SEC CIK: 0001727756

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Yarrow Bioscience, Inc.VYNE · Entity 6871	CHIEF SCIENTIFIC OFFICER	July 23, 2026	July 24, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Yarrow Bioscience, Inc.

Report date July 23, 2026 · Filed July 24, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	95,944	Reported balance After 2026-07-23 transaction · row 1 1 source row Row 1 · 2026-07-23 · Tax withholding · Disposed 15,405 · Balance 95,944 F1: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Foamix Pharmaceuticals Ltd.

Report date March 09, 2020 · Filed March 11, 2020

Section 16 reporting ended · disclosed 2020-03-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	Ending reported balance After 2020-03-09 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2020-03-09 · Disposition to issuer · Disposed 12,333 · Balance 91,303 F1: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2) F2: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement. Row 2 · 2020-03-09 · Disposition to issuer · Disposed 91,303 · Balance 0 F3: Represents Foamix restricted stock unit awards ("Foamix RSUs") that were outstanding immediately prior to the Effective Time, each of which by its terms represented a contingent right to receive one Foamix Share. Each Foamix RSU was assumed by Menlo and converted into a restricted stock unit award relating to Menlo Common Stock (an "Adjusted RSU Award") and has the same terms and conditions as applied to the Foamix RSU immediately prior to the Effective Time. The Adjusted RSU Award will settle in the number of shares of Menlo Common Stock equal to the product obtained by multiplying (i) the number of Foamix Shares subject to the Foamix RSU immediately prior to the Effective Time by (ii) the Exchange Ratio. If the CSRs become convertible, each person holding a Foamix RSU immediately prior to the Effective Time will get additional Adjusted RSU Awards based on the additional shares of Menlo Common Stock that each ordinary Foamix Share will get upon conversion of a CSR.
OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $8.54 · Expires 2026-11-15	Direct	Reported balance After 2020-03-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-03-09 · Disposition to issuer · Disposed 40,000 · Balance 0 F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F4: The ordinary shares underlying this option vest over a period of four years (25% on November 11, 2017 and 6.25% every three months thereafter) ending December 31, 2020.
OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $5.39 · Expires 2027-08-08	Direct	Reported balance After 2020-03-09 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-03-09 · Disposition to issuer · Disposed 13,000 · Balance 0 F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F6: The ordinary shares underlying this option vest over a period of four years (25% on August 8, 2018 and 6.25% every three months thereafter) ending September 30, 2021.
OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $6.35 · Expires 2028-02-27	Direct	Reported balance After 2020-03-09 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-03-09 · Disposition to issuer · Disposed 30,000 · Balance 0 F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F7: The ordinary shares underlying this option vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending March 31, 2022.
OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.77 · Expires 2029-01-01	Direct	Reported balance After 2020-03-09 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-03-09 · Disposition to issuer · Disposed 75,997 · Balance 0 F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F8: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2020 and 6.25% every three months thereafter) ending March 31, 2023.
OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $4.03 · Expires 2030-02-24	Direct	Reported balance After 2020-03-09 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-03-09 · Disposition to issuer · Disposed 96,365 · Balance 0 F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F9: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2021 and 6.25% every three months thereafter) ending March 31, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2)

F2: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement.

F3: Represents Foamix restricted stock unit awards ("Foamix RSUs") that were outstanding immediately prior to the Effective Time, each of which by its terms represented a contingent right to receive one Foamix Share. Each Foamix RSU was assumed by Menlo and converted into a restricted stock unit award relating to Menlo Common Stock (an "Adjusted RSU Award") and has the same terms and conditions as applied to the Foamix RSU immediately prior to the Effective Time. The Adjusted RSU Award will settle in the number of shares of Menlo Common Stock equal to the product obtained by multiplying (i) the number of Foamix Shares subject to the Foamix RSU immediately prior to the Effective Time by (ii) the Exchange Ratio. If the CSRs become convertible, each person holding a Foamix RSU immediately prior to the Effective Time will get additional Adjusted RSU Awards based on the additional shares of Menlo Common Stock that each ordinary Foamix Share will get upon conversion of a CSR.

F4: The ordinary shares underlying this option vest over a period of four years (25% on November 11, 2017 and 6.25% every three months thereafter) ending December 31, 2020.

F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options.

F6: The ordinary shares underlying this option vest over a period of four years (25% on August 8, 2018 and 6.25% every three months thereafter) ending September 30, 2021.

F7: The ordinary shares underlying this option vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending March 31, 2022.

F8: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2020 and 6.25% every three months thereafter) ending March 31, 2023.

F9: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2021 and 6.25% every three months thereafter) ending March 31, 2024.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 09, 2020 Filed Mar 11, 2020 17:41 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	Disposition to issuerOptions · Derivative	96,365	Not disclosed Strike: $4.03	Not disclosed	Disclosure SEC source: 0001209191-20-018202 · doc4.xml · derivative · entry 7 Stuart Iain · CIK 0001727756 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 96,365 shares Expires 2030-02-24 F5 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F9 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2021 and 6.25% every three months thereafter) ending March 31, 2024. Read SEC document
March 09, 2020 Filed Mar 11, 2020 17:41 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	Disposition to issuerOptions · Derivative	75,997	Not disclosed Strike: $3.77	Not disclosed	Disclosure SEC source: 0001209191-20-018202 · doc4.xml · derivative · entry 6 Stuart Iain · CIK 0001727756 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 75,997 shares Expires 2029-01-01 F5 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F8 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2020 and 6.25% every three months thereafter) ending March 31, 2023. Read SEC document
March 09, 2020 Filed Mar 11, 2020 17:41 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	Disposition to issuerOptions · Derivative	30,000	Not disclosed Strike: $6.35	Not disclosed	Disclosure SEC source: 0001209191-20-018202 · doc4.xml · derivative · entry 5 Stuart Iain · CIK 0001727756 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 30,000 shares Expires 2028-02-27 F5 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F7 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending March 31, 2022. Read SEC document
March 09, 2020 Filed Mar 11, 2020 17:41 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	Disposition to issuerOptions · Derivative	13,000	Not disclosed Strike: $5.39	Not disclosed	Disclosure SEC source: 0001209191-20-018202 · doc4.xml · derivative · entry 4 Stuart Iain · CIK 0001727756 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 13,000 shares Expires 2027-08-08 F5 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F6 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on August 8, 2018 and 6.25% every three months thereafter) ending September 30, 2021. Read SEC document
March 09, 2020 Filed Mar 11, 2020 17:41 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	Disposition to issuerOptions · Derivative	40,000	Not disclosed Strike: $8.54	Not disclosed	Disclosure SEC source: 0001209191-20-018202 · doc4.xml · derivative · entry 3 Stuart Iain · CIK 0001727756 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 40,000 shares Expires 2026-11-15 F5 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F4 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on November 11, 2017 and 6.25% every three months thereafter) ending December 31, 2020. Read SEC document
March 09, 2020 Filed Mar 11, 2020 17:41 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	Disposition to issuerOrdinary Shares	91,303	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-018202 · doc4.xml · nonDerivative · entry 2 Stuart Iain · CIK 0001727756 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: Represents Foamix restricted stock unit awards ("Foamix RSUs") that were outstanding immediately prior to the Effective Time, each of which by its terms represented a contingent right to receive one Foamix Share. Each Foamix RSU was assumed by Menlo and converted into a restricted stock unit award relating to Menlo Common Stock (an "Adjusted RSU Award") and has the same terms and conditions as applied to the Foamix RSU immediately prior to the Effective Time. The Adjusted RSU Award will settle in the number of shares of Menlo Common Stock equal to the product obtained by multiplying (i) the number of Foamix Shares subject to the Foamix RSU immediately prior to the Effective Time by (ii) the Exchange Ratio. If the CSRs become convertible, each person holding a Foamix RSU immediately prior to the Effective Time will get additional Adjusted RSU Awards based on the additional shares of Menlo Common Stock that each ordinary Foamix Share will get upon conversion of a CSR. Read SEC document
March 09, 2020 Filed Mar 11, 2020 17:41 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	Disposition to issuerOrdinary Shares	12,333	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-018202 · doc4.xml · nonDerivative · entry 1 Stuart Iain · CIK 0001727756 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,303 F1 · price: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2) F2 · price: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement. Read SEC document
February 24, 2020 Filed Feb 24, 2020 18:39 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	GrantOptions · Derivative	96,365	$0.00 Strike: $4.03	$0.00	Disclosure SEC source: 0001209191-20-012199 · doc4.xml · derivative · entry 2 Stuart Iain · CIK 0001727756 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,365 Underlying: Ordinary Shares · 96,365 shares Expires 2030-02-24 F3 · security: Each option represents a contingent right to purchase one ordinary share of the issuer. F4 · derivative.exercise_date: The ordinary shares underlying these options vest over a 4 year period, with 25% vesting on the first anniversary of the last day of the calendar quarter in which the grant occurred and 6.25% vesting on the last day of each subsequent calendar quarter, ending March 31, 2024. Read SEC document
February 24, 2020 Filed Feb 24, 2020 18:39 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	GrantOrdinary Shares	41,299	$0.00	$0.00	Disclosure SEC source: 0001209191-20-012199 · doc4.xml · nonDerivative · entry 1 Stuart Iain · CIK 0001727756 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,636 F1 · security: This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. F2 · shares: The ordinary shares underlying this restricted share unit award vest over a 4 year period, with 25% vesting on the first anniversary of the last day of the calendar quarter in which the grant occurred and 6.25% vesting on the last day of each subsequent calendar quarter, ending March 31, 2024. Read SEC document
December 31, 2019 Filed Jan 3, 2020 17:23 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	Tax withholdingOrdinary Shares	514	$3.28	$1,685.92	Disclosure SEC source: 0001209191-20-001245 · doc4.xml · nonDerivative · entry 1 Stuart Iain · CIK 0001727756 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,337 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of the restricted share units and does not represent a sale by the Reporting Person. Read SEC document
September 30, 2019 Filed Oct 2, 2019 16:20 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	Tax withholdingOrdinary Shares	673	$3.07	$2,066.11	Disclosure SEC source: 0001209191-19-051671 · doc4.xml · nonDerivative · entry 1 Stuart Iain · CIK 0001727756 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,851 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of the restricted share units and does not represent a sale by the Reporting Person. Read SEC document
July 01, 2019 Filed Jul 3, 2019 16:26 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	SaleOrdinary Shares	951	$2.35	$2,234.85	Disclosure SEC source: 0001209191-19-041101 · doc4.xml · nonDerivative · entry 1 Stuart Iain · CIK 0001727756 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,524 F1 · security: For administrative reasons, the Reporting Person's then-existing long term incentives were amended in December 2018 to provide that, effective as of January 1, 2019, the vesting of any unvested restricted share units or options that were granted pursuant to such awards shall take place at the end of the calendar quarter in which the award was otherwise scheduled to vest. F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. This sale is mandated by the Issuer's non-discretionary policy that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document
April 01, 2019 Filed Apr 3, 2019 16:38 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	SaleOrdinary Shares	1,696	$3.75	$6,360.00	Disclosure SEC source: 0001209191-19-023170 · doc4.xml · nonDerivative · entry 1 Stuart Iain · CIK 0001727756 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,475 F1 · security: For administrative reasons, the Reporting Person's then-existing long term incentives were amended in December 2018 to provide that, effective as of January 1, 2019, the vesting of any unvested restricted share units or options that were granted pursuant to such awards shall take place at the end of the calendar quarter in which the award was otherwise scheduled to vest. F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. This sale is mandated by the Issuer's non-discretionary policy that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document
January 01, 2019 Filed Jan 3, 2019 16:08 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	GrantOption (right to buy) · Derivative	75,997	$3.77 Strike: $3.77	$286,508.69	Disclosure SEC source: 0001178913-19-000048 · zk1922434.xml · derivative · entry 2 Stuart Iain · CIK 0001727756 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,997 Underlying: Ordinary Shares · 75,997 shares Expires 2029-01-01 F2 · derivative.exercise_date: The ordinary shares underlying these options vest over a period of four years from the end of the calendar quarter in which the grant was made (25% on March 31, 2020, and 6.25% every three months thereafter on the last day of the quarter) ending March 31, 2023, subject to the reporting person's continuous service with the Issuer as of each such vesting date. Read SEC document
January 01, 2019 Filed Jan 3, 2019 16:08 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	GrantOrdinary Shares	32,569	$0.00	$0.00	Disclosure SEC source: 0001178913-19-000048 · zk1922434.xml · nonDerivative · entry 1 Stuart Iain · CIK 0001727756 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,171 F1 · shares: These shares are represented by restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer. The ordinary shares underlying this restricted share unit award vest over a period of four years from the end of the calendar quarter in which the grant was made (25% on March 31, 2020, and 6.25% every three months thereaf-ter on the last day of the quarter) ending March 31, 2023, subject to the reporting person's continuous service with the Issuer as of each such vesting date. Read SEC document
November 08, 2018 Filed Nov 13, 2018 06:16 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	SaleOrdinary Shares	683	$4.58	$3,128.14	Disclosure SEC source: 0001178913-18-002900 · zk1822262.xml · nonDerivative · entry 1 Stuart Iain · CIK 0001727756 · SVP R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,602 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. This sale is mandated by the Issuer's non-discretionary policy that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document
August 08, 2018 Filed Aug 9, 2018 16:05 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	SaleOrdinary Shares	2,715	$5.68	$15,421.20	Disclosure SEC source: 0001178913-18-002363 · zk1822017.xml · nonDerivative · entry 1 Stuart Iain · CIK 0001727756 · SVP R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,285 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. This sale is mandated by the Issuer's non-discretionary policy that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discre-tionary trade by the reporting person. Read SEC document
February 27, 2018 Filed Feb 28, 2018 16:12 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	GrantOptions · Derivative	30,000	$6.35 Strike: $6.35	$190,500.00	Disclosure SEC source: 0001178913-18-000726 · zk1821309.xml · derivative · entry 2 Stuart Iain · CIK 0001727756 · SVP R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Ordinary Shares · 30,000 shares Expires 2028-02-27 F4 · security: Each option represents a contingent right to purchase one ordinary share of the issuer. F5 · derivative.exercise_date: The ordinary shares underlying these options vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022. Read SEC document
February 27, 2018 Filed Feb 28, 2018 16:12 UTC	Foamix Pharmaceuticals Ltd. FOMX · Entity 150527	GrantOrdinary Shares	10,000	$0.00	$0.00	Disclosure SEC source: 0001178913-18-000726 · zk1821309.xml · nonDerivative · entry 1 Stuart Iain · CIK 0001727756 · SVP R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,000 F2 · shares: The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022. F1 · price: This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. F3 · balance_after: The issuer's method of reporting restricted share units has been revised to report such grants in Table I rather than as previously reported in Table II. Accordingly, this amount includes (i) 27,000 ordinary shares subject to unvested restricted share units that were previously reported in Table II of the reporting person's Form 3 as a derivative security and (ii) the 10,000 ordinary shares sub-ject to unvested restricted share units granted on February 27, 2018 and first reported on this Form 4. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.